ScholarIQanswers from OpenAlex & ORCID
Bruce E. Sands
ResearcherPublications, citations & collaboration network
Bruce E. Sands is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Bruce E. Sands have?
ScholarIQindexed works
Bruce E. Sands has 1,067 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Bruce E. Sands have?
ScholarIQcitation count
Bruce E. Sands has 66,805 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Bruce E. Sands?
ScholarIQh-index
Bruce E. Sands has an h-index of 108 in OpenAlex.
What is the i10-index of Bruce E. Sands?
ScholarIQi10-index
Bruce E. Sands has an i10-index of 366 in OpenAlex.
What is the ORCID of Bruce E. Sands?
ScholarIQorcid
The ORCID for Bruce E. Sands is on the source record.
What is the OpenAlex record for Bruce E. Sands?
ScholarIQopenalex
The OpenAlex for Bruce E. Sands is on the source record.
What are the most-cited papers on Bruce E. Sands?
ScholarIQmost cited works
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands, Stephen B. Hanauer, Jean‐Frédéric Colombel, William J. Sandborn, Gert Van Assche, Jeffrey Axler, Hyo Jong Kim, Silvio Danese, Irving H. Fox, Catherine Milch, Serap Sankoh, Tim Wyant, Jing Xu, Asit Parikh
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
Dan Turner, Amanda Ricciuto, Ayanna Lewis, Ferdinando D’Amico, Jasbir Dhaliwal, Anne M. Griffiths, Dominik Bettenworth, William J. Sandborn, Bruce E. Sands, Walter Reinisch, Jürgen Schölmerich, Willem A. Bemelman, Silvio Danese, Jean Yves Mary, David T. Rubin, Jean‐Frédéric Colombel, Laurent Peyrin‐Biroulet, Iris Dotan, María T. Abreu, Axel Dignaß
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
Laurent Peyrin‐Biroulet, William J. Sandborn, Bruce E. Sands, Walter Reinisch, Willem A. Bemelman, Robert V. Bryant, Geert D’Haens, Iris Dotan, Marla C. Dubinsky, Brian G. Feagan, Gionata Fiorino, Richard B. Gearry, Suneeta Krishnareddy, Péter L. Lakatos, Edward V. Loftus, Philippe Marteau, Pia Munkholm, Travis B. Murdoch, Íngrid Ordás, Remo Panaccione, Robert H. Riddell, Joannie Ruel, David T. Rubin, Mark Samaan, Corey A. Siegel, Mark S. Silverberg, Jaap Stoker, S Schreiber, Simon Travis, Gert Van Assche, Silvio Danese, Julián Panés, Guillaume Bouguen, Sarah O’Donnell, Benjamin Pariente, Shawn Winer, Stephen B. Hanauer, J -F Colombel
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Brian G. Feagan, William J. Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R. Friedman, Marion Blank, Jewel Johanns, Long-Long Gao, Miao Ye, Omoniyi J. Adedokun, Bruce E. Sands, Stephen B. Hanauer, Séverine Vermeire, Stephan R. Targan, Subrata Ghosh, Willem J. de Villiers, Jean–Frédéric Colombel, Zsolt Tulassay, Ursula Seidler, Bruce Salzberg, Pierre Desreumaux, Scott D. Lee, Edward V. Loftus, Levinus A. Dieleman, Seymour Katz, Paul Rutgeerts
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn, Chinyu Su, Bruce E. Sands, Geert D’Haens, Séverine Vermeire, Stefan Schreiber, Silvio Danese, Brian G. Feagan, Walter Reinisch, Wojciech Niezychowski, Gary S. Friedman, Nervin Lawendy, Dahong Yu, Deborah Woodworth, Arnab Mukherjee, Haiying Zhang, Paul J. Healey, Julián Panés